Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/129478
DC FieldValueLanguage
dc.contributor.authorFerrera Alayón, Laura-
dc.contributor.authorSalas Salas, Barbara-
dc.contributor.authorCabrera Diaz-Saavedra, Raquel-
dc.contributor.authorRamos Ortiz, Anais-
dc.contributor.authorZafra Martin, Juan-
dc.contributor.authorLara Jimenez, Pedro Carlos-
dc.contributor.authorLloret Sáez-Bravo, Marta-
dc.date.accessioned2024-03-18T10:38:16Z-
dc.date.available2024-03-18T10:38:16Z-
dc.date.issued2023-
dc.identifier.issn1507-1367-
dc.identifier.otherScopus-
dc.identifier.urihttp://hdl.handle.net/10553/129478-
dc.description.abstractBackground: Oropharyngeal dysphagia (OD) occurs in up to 40% of head and neck cancer (HNC) patients before treatment and remains a common symptom (23–60%) after oncological treatments, leading to several consequences. Early detection is essential for effective swallowing-rehabilitation and nutritional-support. The increased radiosensitivity of tumors associated with human papillomavirus (HPV) and advances in imaging techniques have stimulated research into deintensified strategies to minimize radiotherapy (RT) side effects. The purposes of the study are to establish the percentage of patients with HNC who are candidates to RT who are at risk of dysphagia [Eating Assessment Tool (EAT) score ≥ 3], determine if tumor location and previous surgery were related to a higher risk of dysphagia and if patients suffering severe toxicity during cancer therapy are at greater risk of posttreatment-dysphagia.Materials and methods: Patients diagnosed of HNC who were referred to RT treatment at our Radiation Oncology Department were prospectively included. Questionnaire EAT-10 was filled in the first assessment used as a screening tool and repeated one month after treatment. Treatment toxicity was established according to common toxicity criteria adverse effects (CTCAE4.03).Results: From November 2019 to January 2021, 72 patients were included. All completed pretreatment EAT-10 questionnaire. The mean (SD) score of the pretreatment EAT-10 was 7.26 ± 11.19 and 43.1% were at dysphagia risk. Patients with tumors located in the oral cavity, oropharynx and those that had received surgery prior to RT had higher risk than the rest of locations or those who had not previous surgery (p = 0.001 and p = 0.002, respectively). After oncological treatment 95.83% completed EAT-10 post-treatment and 45,6% showed positive EAT-10 score.Conclusions: Patients with tumors in the oral cavity or oropharynx, presenting in advanced stage, and who previously received surgery are at higher risk of developing dysphagia. The EAT-10 is a simple tool that can help us identify those patients and refer them for an intensive evaluation to reduce dysphagia-consequences.-
dc.languageeng-
dc.relation.ispartofReports of Practical Oncology and Radiotherapy-
dc.sourceReports of Practical Oncology and Radiotherapy [ISSN 1507-1367], v. 28 (6), p. 756-763, (Enero 2023)-
dc.subject320101 Oncología-
dc.subject.otherDysphagia-
dc.subject.otherHead And Neck Cancer-
dc.subject.otherRadiation Oncology Department-
dc.titleScreening oropharyngeal dysphagia in patients with head and neck cancer in a radiation oncology department-
dc.typeinfo:eu-repo/semantics/Article-
dc.typeArticle-
dc.identifier.doi10.5603/rpor.98732-
dc.identifier.scopus85187122754-
dc.identifier.isi001175820300006-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.orcidNO DATA-
dc.contributor.authorscopusid58926001300-
dc.contributor.authorscopusid57225345847-
dc.contributor.authorscopusid58926431500-
dc.contributor.authorscopusid58927299600-
dc.contributor.authorscopusid57700718200-
dc.contributor.authorscopusid57533662400-
dc.contributor.authorscopusid57211187914-
dc.identifier.eissn2083-4640-
dc.description.lastpage763-
dc.identifier.issue6-
dc.description.firstpage756-
dc.relation.volume28-
dc.investigacionCiencias de la Salud-
dc.type2Artículo-
dc.contributor.daisngid55702935-
dc.contributor.daisngid55761362-
dc.contributor.daisngid55687858-
dc.contributor.daisngid54584363-
dc.contributor.daisngid47867455-
dc.contributor.daisngid9166013-
dc.contributor.daisngid50404070-
dc.description.numberofpages8-
dc.utils.revision-
dc.contributor.wosstandardWOS:Alayón, LF-
dc.contributor.wosstandardWOS:Salas, BS-
dc.contributor.wosstandardWOS:Diaz-Saavedra, RC-
dc.contributor.wosstandardWOS:Ortiz, AR-
dc.contributor.wosstandardWOS:Martin, JZ-
dc.contributor.wosstandardWOS:Jimenez, PCL-
dc.contributor.wosstandardWOS:Sáez-Bravo, ML-
dc.date.coverdateEnero 2023-
dc.identifier.ulpgc-
dc.contributor.buulpgcBU-MED-
dc.description.sjr0,376-
dc.description.sjrqQ3-
dc.description.esciESCI-
dc.description.miaricds9,9-
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.deptDepartamento de Ciencias Clínicas-
crisitem.author.fullNameLloret Sáez-Bravo, Marta-
Appears in Collections:Artículos
Show simple item record

Page view(s)

72
checked on Oct 5, 2024

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.